[{"id":"0acb1841-b2e1-41a5-918e-ca85a37b180c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04946890","created_at":"2021-07-01T14:54:38.224Z","updated_at":"2024-07-02T16:36:28.403Z","phase":"Phase 1/2","brief_title":"A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04946890","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MRX2843"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2021-07-01"}]